Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given prulifloxacin in the routine care in Greece. This observational, prospective study, conducted in 15 hospital-based clinics across Greece, enrolled outpatients >40 years old, with moderate-to-severe AECB, for whom the physician had decided to initiate treatment with prulifloxacin. Data were collected at prulifloxacin onset (baseline), 7–10 days after baseline, and at least 28 days after therapy completion. Between 23 November 2015 and 27 January 2018, 305 patients (males: 76.4%; mean (standard deviation) (SD) age: 69.7 (9.8) years; Anthonisen type I/II: 94.8%; chronic bronchitis duration >10 years: 24.9%) were consecutively enrolled. At baseline, >80% had increased sputum volume, cough, dyspnoea, and sputum purulence. Prulifloxacin improved symptoms in 99.7% of the patients after a mean (SD) of 5.47 (3.57) days, while symptoms fully recovered after a mean (SD) of 10.22 (5.00) days in 95.4%. The rate of adverse events related to prulifloxacin was 1.3% (serious: 0.7%). In the routine care in Greece, prulifloxacin was highly effective in moderate-to-severe AECB, while displaying a predictable safety profile.

中文翻译：

---

普卢利沙星对慢性支气管炎中度至重度急性发作的疗效：现实临床实践中的非介入性、多中心、前瞻性研究——“AIOLOS”研究


关于普利沙星治疗慢性支气管炎急性加重 (AECB) 有效性的真实世界证据有限。因此，本研究旨在评估希腊在常规护理中接受普卢利沙星治疗的中重度 AECB 患者症状改善和消退的比率和时间。这项观察性、前瞻性研究在希腊 15 家医院诊所进行，招募了 >40 岁、患有中度至重度 AECB 的门诊患者，医生决定开始使用普卢利沙星进行治疗。在普卢利沙星开始使用时（基线）、基线后 7-10 天以及治疗完成后至少 28 天收集数据。 2015年11月23日至2018年1月27日期间，305名患者（男性：76.4%；平均（标准差）（SD）年龄：69.7（9.8）岁；Anthonisen I/II型：94.8%；慢性支气管炎病程>10年：24.9 %) 连续入学。基线时，>80% 出现痰量增加、咳嗽、呼吸困难和脓痰。平均 (SD) 5.47 (3.57) 天后，普卢利沙星改善了 99.7% 的患者症状，而 95.4% 的患者在平均 (SD) 10.22 (5.00) 天后症状完全恢复。与普卢利沙星相关的不良事件发生率为 1.3%（严重：0.7%）。在希腊的常规护理中，普卢利沙星对中度至重度 AECB 非常有效，同时显示出可预测的安全性。